33 results
Thumbnail

D1.64 - Distinct and Overlapping Sensitization Patterns to Crustacean and House Dust Mite Allergens in Tropical Allergy

Thumbnail

D1.72 - Assessing potential influencing factors on allergic reaction to the cumulative dose given on an extra day within oral food challenge in food-allergic children

Thumbnail

D1.75 - Association of SCORAD Values with Skin Barrier Function Indicators in Patients with Atopic Dermatitis

Thumbnail

D1.61 - Shrimp Tropomyosin as a Selective Allergen in a Case of Food Allergy: The Value of Individualized Molecular Analysis

Thumbnail

D1.62 - Thermal stress alters the allergen and proteome profile of the redclaw crayfish (Cherax quadicarinatus)

Thumbnail

D1.63 - Suspected Hypersensitivity to Non-Nutritive Sweeteners With Recurrent Respiratory Manifestations in a Pediatric Patient

Thumbnail

D1.65 - Selective Allergy to Large Prawn: Identification of a Projectin-Derived IgE-Binding Protein

Thumbnail

D1.66 - Allergy profiling in selective goat and sheep milk allergy

Thumbnail

D1.67 - Comparison of machine learning models for grass carp allergy diagnosis

Thumbnail

D1.70 - IgE-sensitization to allergens in plant-based drinks in children with cow’s milk allergy

Thumbnail

D1.71 - Can an allergist predict the development of allergies? A Clinical case of dizygotic twins with divergent outcomes

Thumbnail

D1.73 - Date Palm or Grass pollen rhinoconjuctivitis in a patient with watermelon allergy?

Thumbnail

D1.74 - Sunflower Seed–Induced Anaphylaxis: Allergenic Characterization and Evidence of Cross-Reactivity with Niger Seeds

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial